In concordance, the administration of SFN also inhibited the susceptibility to develop depression under stress conditions [47] and suppressed the anxiodepressive-like behaviors related to neuropathic pain by normalizing the expression of Nrf2 and HO-1 in the hippocampus and prefrontal cortex [48]. The gene discussed is NFE2L2; the disease is major depressive disorder.